Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population.

Abstract:

:Pertussis has re-emerged as a public health problem in Canada in recent years, emphasizing concerns about the effectiveness of the currently licensed whole-cell vaccine. Following a 1994 outbreak in Nova Scotia, we conducted a case-control study of 483 children aged < 10 years to assess vaccine effectiveness. Ninety-three percent of children aged 6 months and above had received three or more doses of vaccine, however, only 78% had received age-appropriate immunization. Among children aged 4 years and more, vaccine effectiveness against laboratory-confirmed pertussis was 57% (95% CI, 23-77%) for age-appropriate immunization (five doses) vs partial or no immunization. Vaccine effectiveness increased with increasing number of doses from 25% (95% CI, -58-65%) for three or more doses to 55% (95% CI, -15-83%) for five doses, compared with 0-2 doses.

journal_name

Vaccine

journal_title

Vaccine

authors

Bentsi-Enchill AD,Halperin SA,Scott J,MacIsaac K,Duclos P

doi

10.1016/s0264-410x(96)00176-4

subject

Has Abstract

pub_date

1997-02-01 00:00:00

pages

301-6

issue

3

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(96)00176-4

journal_volume

15

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Immunization education for internal medicine residents: A cluster-randomized controlled trial.

    abstract:PURPOSE:The aims of this study are to evaluate the impact of a novel immunization curriculum based on the Preferred Cognitive Styles and Decision Making Model (PCSDM) on internal medicine (IM) resident continuity clinic patient panel immunization rates, as well as resident immunization knowledge, attitudes, and practic...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2018.02.082

    authors: Whitaker JA,Poland CM,Beckman TJ,Bundrick JB,Chaudhry R,Grill DE,Halvorsen AJ,Huber JM,Kasten MJ,Mauck KF,Mehta RA,Olson T,Thomas KG,Thomas MR,Virk A,Wingo MT,Poland GA

    更新日期:2018-03-27 00:00:00

  • Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.

    abstract::The aim of this study was to investigate whether, the vaccine Priorix causes less immediate injection pain than MMR-II in vaccination of infants aged 18-24 months who were offered vaccine against measles, mumps and rubella. The infants were randomised into one of the two vaccine groups (Priorix/MMR-II in a double-blin...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2006.05.004

    authors: Knutsson N,Jansson UB,Alm B

    更新日期:2006-07-26 00:00:00

  • Development and immunological evaluation of HLA-specific chronic myeloid leukemia polyepitope vaccine in Chinese population.

    abstract:BACKGROUND:BCR/ABL and Wilms' tumor 1 (WT1) are an ideal tumor associated antigens which can be used to develop a potential chronic myeloid leukemia (CML) dentritic cell (DC) vaccine. Here, we constructed a novel polyepitope vaccine which used recombinant lentiviral vector carrying BCR/ABL and WT1 genes, and determined...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.04.041

    authors: Dong W,Zhang J,Shao N,Tian T,Li L,Jian J,Zang S,Ma D,Ji C

    更新日期:2014-06-12 00:00:00

  • Characterization of Schistosoma mansoni 44.7/56.8 kDa egg antigens recognized by human monoclonal antibodies which induce protection against experimental infection and proliferation of peripheral blood mononuclear cells from schistosomiasis patients.

    abstract::We described here the characterization of Schistosoma mansoni egg antigens recognized by human monoclonal antibodies B10 (HmAb-B10) and D5 (HmAb-D5). SDS-PAGE and Western blot analysis revealed that these monoclonals recognized two antigens of M W 44.7/56.8 kDa, with pI of 7.0 and 7.8, respectively. The passive transf...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(96)00305-2

    authors: Hirsch C,Almeida CA,Doughty BL,Goes AM

    更新日期:1997-06-01 00:00:00

  • Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

    abstract::In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the highly attenuated vaccinia virus strains, MVA and NYVAC, efficiently expressing in the same locus (TK) and under the same viral promoter the codon optimized HIV-1 genes encoding gp120 and Gag-Po...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.090

    authors: Gómez CE,Nájera JL,Jiménez EP,Jiménez V,Wagner R,Graf M,Frachette MJ,Liljeström P,Pantaleo G,Esteban M

    更新日期:2007-04-12 00:00:00

  • Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

    abstract::A conjugate vaccine against meningococcus A and C was prepared using the non-toxic mutant of diphtheria toxin CRM 197 as a carrier protein. Capsular polysaccharides of Neisseria meningitidis group A and C were hydrolysed and the resulting oligosaccharides were then coupled to CRM 197 in order to obtain conjugates with...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/0264-410x(92)90091-w

    authors: Costantino P,Viti S,Podda A,Velmonte MA,Nencioni L,Rappuoli R

    更新日期:1992-01-01 00:00:00

  • Development of a recombinant vaccine against aerosolized plague.

    abstract::Although few diseases have had a greater impact on human history, currently there is no vaccine available for protection against plague that is licensed by the Food and Drug Administration (FDA). DynPort Vaccine Company LLC, a CSC company (DVC), is managing the advanced development of a recombinant plague vaccine (rF1...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.01.071

    authors: Morris SR

    更新日期:2007-04-20 00:00:00

  • Effect of congestive heart failure on humoral and ex vivo cellular immune responses to influenza vaccination in older adults.

    abstract::This study examined the effect of congestive heart failure (CHF) on immune responses to influenza vaccination (2000-2001 preparation) in three groups of older adults including healthy, Class II and Class III/IV CHF. Serum antibody titers measured by hemagglutination inhibition (HI), and interferon-gamma (IFN-gamma), i...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.08.032

    authors: McElhaney JE,Herre JM,Lawson ML,Cole SK,Burke BL,Hooton JW

    更新日期:2004-01-26 00:00:00

  • Variable-number tandem repeat markers for identification of Brucella abortus 82 and 75/79-AV vaccine strains.

    abstract::In Russia, live vaccine strains Brucella abortus 82 and B. abortus 75/79-AV have been widely and extensively utilized for specific prophylaxis of cattle brucellosis. To differentiate these vaccine strains from each other and laboratory collection of other vaccine (n=4), reference (n=15) and field Brucella strains (n=6...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.03.051

    authors: Kulakov YK,Zheludkov MM,Sclyarov OD

    更新日期:2010-10-01 00:00:00

  • Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.

    abstract:BACKGROUND:PCV13 (conjugated polysaccharide) and PPSV23 (polysaccharide only) are two licensed vaccines targeting S. pneumoniae. The role of CD4 T-cell responses in pneumococcal vaccines among healthy participants and their impact on antibodies is not yet known. METHODS:Ten adults (5 old and 5 young) received PCV13 (p...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.12.023

    authors: Sterrett S,Peng BJ,Burton RL,LaFon DC,Westfall AO,Singh S,Pride M,Anderson AS,Ippolito GC,Schroeder HW Jr,Nahm MH,Krishna Prasad A,Goepfert P,Bansal A

    更新日期:2020-02-11 00:00:00

  • Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant.

    abstract:BACKGROUND:The development of a vaccine against the human gastric pathogen Helicobacter pylori, the main causative agent of gastric adenocarcinoma, has been hampered by a number of issues, including the lack of a mucosal adjuvant for use in humans. Heat shock proteins (Hsp), highly conserved molecules expressed by both...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.02.051

    authors: Chionh YT,Arulmuruganar A,Venditti E,Ng GZ,Han JX,Entwisle C,Ang CS,Colaco CA,McNulty S,Sutton P

    更新日期:2014-04-25 00:00:00

  • Typhoid fever vaccination strategies.

    abstract::Typhoid vaccination is an important component of typhoid fever prevention and control, and is recommended for public health programmatic use in both endemic and outbreak settings. We reviewed experiences with various vaccination strategies using the currently available typhoid vaccines (injectable Vi polysaccharide va...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.04.028

    authors: Date KA,Bentsi-Enchill A,Marks F,Fox K

    更新日期:2015-06-19 00:00:00

  • The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012.

    abstract:BACKGROUND:Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Ze...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.04.013

    authors: Turner N,Pierse N,Bissielo A,Huang QS,Baker MG,Widdowson MA,Kelly H,SHIVERS investigation team.

    更新日期:2014-06-17 00:00:00

  • Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and β-glucan.

    abstract::Polymeric nanoparticles (NPs) of poly (lactic-co-glycolic) acid (PLGA) possess adjuvant properties. To date, there are few studies exploring their application as antigen carriers for vaccination of fish. This study presents a preclinical assessment of the early innate and adaptive immune responses in Atlantic salmon f...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.08.087

    authors: Fredriksen BN,Sævareid K,McAuley L,Lane ME,Bøgwald J,Dalmo RA

    更新日期:2011-10-26 00:00:00

  • Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.

    abstract:BACKGROUND:The Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program is the immunization safety monitoring component of FDA's Mini-Sentinel project, a program to actively monitor the safety of medical products using electronic health information. FDA sought to assess the surveillance capabilities of this ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.04.088

    authors: Baker MA,Nguyen M,Cole DV,Lee GM,Lieu TA

    更新日期:2013-12-30 00:00:00

  • A humanized monoclonal antibody targeting Staphylococcus aureus.

    abstract::This current presentation describes the in vitro and in vivo characterization of Aurexis (tefibazumab), a humanized monoclonal antibody that exhibits a high affinity and specificity and for the Staphylococcus aureus MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) protein ClfA. Aurexis inhi...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2004.08.015

    authors: Patti JM

    更新日期:2004-12-06 00:00:00

  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials.

    abstract:BACKGROUND:Efforts to develop a Clostridium difficile vaccine are underway; identification of patients at risk for C. difficile infection (CDI) is critical to inform vaccine trials. We identified groups at high risk of CDI ≥ 2 8 days after hospital discharge. METHODS:Hospital discharge data and pharmacy data from two ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.09.078

    authors: Baggs J,Yousey-Hindes K,Ashley ED,Meek J,Dumyati G,Cohen J,Wise ME,McDonald LC,Lessa FC

    更新日期:2015-11-17 00:00:00

  • An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions.

    abstract::Lassa virus (LASV) causes a severe hemorrhagic fever endemic throughout western Africa. Because of the ability to cause lethal disease in humans, limited treatment options, and potential as a bioweapon, the need for vaccines to prevent LASV epidemic is urgent. However, LASV vaccine development has been hindered by the...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.07.101

    authors: Li Q,Liu Q,Huang W,Wu J,Nie J,Wang M,Zhao C,Zhang L,Wang Y

    更新日期:2017-09-12 00:00:00

  • A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).

    abstract::The anti-tumor immunologic effects of plasmid DNA vaccines encoding human carcinoembryonic antigen (CEA) fused to mouse granulocyte/macrophage colony-stimulating factor (GM-CSF) were examined. Immunization of C57BL/6 mice with the CEA-GMCSF fusion plasmids in a three injection, high-dose immunization schedule led to T...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.08.043

    authors: Lima J,Jenkins C,Guerrero A,Triozzi PL,Shaw DR,Strong TV

    更新日期:2005-01-26 00:00:00

  • Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines.

    abstract::The adjuvant effect of Quil A on the primary antibody response of mice to pneumococcal capsular polysaccharide conjugates was examined. Quil A increased the anti-capsular polysaccharide antibody titres, the protection against Streptococcus pneumoniae, and the opsonic capacity of the antibodies as measured in a newly d...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)90151-1

    authors: DeVelasco EA,Dekker HA,Antal P,Jalink KP,van Strijp JA,Verheul AF,Verhoef J,Snippe H

    更新日期:1994-11-01 00:00:00

  • A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination.

    abstract:OBJECTIVE:To determine human papillomavirus (HPV) prevalence and type-distribution in women from South Asia, with and without cervical lesions, in order to estimate the impact of an HPV 16/18 prophylactic vaccine in this region and to assess additional types that should be incorporated in new vaccines. METHODS:A meta-...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2008.03.047

    authors: Bhatla N,Lal N,Bao YP,Ng T,Qiao YL

    更新日期:2008-06-02 00:00:00

  • Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).

    abstract:BACKGROUND:We have shown that the intradermal (ID) administration of an HIV-1 lipopeptide candidate vaccine (LIPO-4) is well tolerated in healthy volunteers, with one fifth the IM dose delivered by this route inducing HIV-1-specific CD8(+) T-cell responses of a magnitude and quality similar to those achieved by IM admi...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2013.06.102

    authors: Launay O,Surenaud M,Desaint C,Ben Hamouda N,Pialoux G,Bonnet B,Poizot-Martin I,Gonzales G,Cuzin L,Bourgault-Villada I,Lévy Y,Choppin J,Durier C

    更新日期:2013-09-13 00:00:00

  • Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.

    abstract::In a single-center study, 66 healthy volunteers aged between 18 and 50years were randomized to be immunized against rabies with three different injection routes: intradermal with DebioJect™ (IDJ), standard intradermal with classical needle (IDS), also called Mantoux method, and intramuscular with classical needle (IM)...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.09.069

    authors: Vescovo P,Rettby N,Ramaniraka N,Liberman J,Hart K,Cachemaille A,Piveteau LD,Zanoni R,Bart PA,Pantaleo G

    更新日期:2017-03-27 00:00:00

  • Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.

    abstract:BACKGROUND:Germany introduced routine varicella (V) vaccination in 2004. Due to a slightly increased risk of febrile convulsions after first-dose application of combined measles-mumps-rubella-varicella (MMRV) vaccine separate first-dose vaccinations with MMR and monovalent V vaccine were recommended in September 2011. ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.12.065

    authors: Streng A,Liese JG

    更新日期:2014-02-12 00:00:00

  • Induction of cross-reactive immune responses to NTS-DBL-1alpha/x of PfEMP1 and in vivo protection on challenge with Plasmodium falciparum.

    abstract::The interactions of Plasmodium falciparum infected erythrocytes parasitized red blood cells (pRBC) with endothelial receptors and erythrocytes are mediated by multiple Duffy-binding like (DBL) and cysteine-rich interdomain region (CIDR) domains harboured in the Plasmodium falciparum erythrocyte membrane protein 1 (PfE...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.05.030

    authors: Ahuja S,Pettersson F,Moll K,Jonsson C,Wahlgren M,Chen Q

    更新日期:2006-08-28 00:00:00

  • Implementation of the Standards for adult immunization practice: A survey of U.S. Health care providers.

    abstract::The revised Standards for Adult Immunization Practice ("Standards"), published in 2014, recommend routine vaccination assessment, strong provider recommendation, vaccine administration or referral, and documentation of vaccines administered into immunization information systems (IIS). We assessed clinician and pharmac...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.05.073

    authors: Granade CJ,Parker Fiebelkorn A,Black CL,Lutz CS,Srivastav A,Bridges CB,Ball SW,Devlin RG,Cloud AJ,Kim DK

    更新日期:2020-07-14 00:00:00

  • Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses.

    abstract::DNA immunization is an attractive form of vaccination, which has shown promising results only in small animal models. There is a need to develop efficient gene delivery systems. We previously demonstrated that oxidized (OM) and reduced mannan (RM) complexed to ovalbumin DNA via poly-l-lysine (PLL), were able to genera...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.05.008

    authors: Tang CK,Sheng KC,Pouniotis D,Esparon S,Son HY,Kim CW,Pietersz GA,Apostolopoulos V

    更新日期:2008-07-23 00:00:00

  • Cost-effectiveness of childhood rotavirus vaccination in Taiwan.

    abstract:OBJECTIVE:Rotavirus is the most common cause of severe diarrhea in children. Two rotavirus vaccines (RotaTeq and Rotarix) have been licensed in Taiwan. We have investigated whether routine infant immunization with either vaccine could be cost-effective in Taiwan. METHODS:We modeled specific disease outcomes including ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.023

    authors: Wu CL,Yang YC,Huang LM,Chen KT

    更新日期:2009-03-04 00:00:00

  • Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines.

    abstract:BACKGROUND:The potential for development of autoimmune diseases after vaccination with new vaccines containing novel adjuvants is a theoretical concern. Randomised, placebo-controlled trials are the best method for assessing a potential causal relationship between an adverse event and vaccination, but usually have a sa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.01.042

    authors: Tavares Da Silva F,De Keyser F,Lambert PH,Robinson WH,Westhovens R,Sindic C

    更新日期:2013-04-03 00:00:00

  • A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

    abstract::PSMA-VRP is a propagation defective, viral replicon vector system encoding PSMA under phase I evaluation for patients with castration resistant metastatic prostate cancer (CRPC). The product is derived from an attenuated strain of the alphavirus, Venezuelan Equine Encephalitis (VEE) virus, and incorporates multiple re...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.11.096

    authors: Slovin SF,Kehoe M,Durso R,Fernandez C,Olson W,Gao JP,Israel R,Scher HI,Morris S

    更新日期:2013-01-30 00:00:00